{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:13:45Z","timestamp":1785500025561,"version":"3.56.0"},"posted":{"date-parts":[[2023,12,22]]},"group-title":"In Review","reference-count":62,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,11,29]]},"abstract":"<title>Abstract<\/title>\n        <p>Background: Associations between phenotypic traits, environmental exposures, and Parkinson\u2019s disease have largely been evaluated one-by-one, piecemeal, and pre-selections. A comprehensive picture of comorbidities, phenotypes, exposures, and polypharmacy characterizing the complexity and heterogeneity of real-world patients presenting to academic movement disorders clinics in the US is missing.\nObjectives: To portrait the complexity of features associated with patients with Parkinson\u2019s disease in a study of 933 cases and 291 controls enrolled in the Harvard Biomarkers Study.\nMethods: The primary analysis evaluated 64 health features for associations with Parkinson\u2019s using logistic regression adjusting for age and sex. We adjusted for multiple testing using the false discovery rate (FDR) with \u00a3 0.05 indicating statistical significance. Exploratory analyses examined feature correlation clusters and feature combinations.\nResults: Depression (OR = 3.11, 95% CI 2.1 to 4.71), anxiety (OR = 3.31, 95% CI 2.01-5.75), sleep apnea (OR 2.58, 95% CI 1.47-4.92), and restless leg syndrome (RLS; OR 4.12, 95% CI 1.81-12.1) were significantly more common in patients with Parkinson\u2019s than in controls adjusting for age and sex with FDR  \u00a3 0.05. The prevalence of depression, anxiety, sleep apnea, and RLS were correlated, and these diseases formed part of a larger cluster of mood traits and sleep traits linked to PD. Exposures to pesticides (OR 1.87, 95% CI 1.37-2.6), head trauma (OR 2.33, 95% CI 1.51-3.73), and smoking (OR 0.57, 95% CI 0.43-0.75) were significantly associated with the disease consistent with previous studies. Vitamin supplementation with cholecalciferol (OR 2.18, 95% CI 1.4-3.45) and coenzyme Q10 (OR 2.98, 95% CI 1.89-4.92) was more commonly used by patients than controls. Cumulatively, 43% (398 of 933) of Parkinson\u2019s patients had at least one psychiatric or sleep disorder, compared to 21% (60 of 291) of healthy controls.\nConclusions: 43% of Parkinson\u2019s patients seen at Harvard-affiliated teaching hospitals have depression, anxiety, and disordered sleep. This syndromic cluster of mood and sleep traits may be pathophysiologically linked and clinically important.<\/p>","DOI":"10.21203\/rs.3.rs-3683455\/v1","type":"posted-content","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T15:57:50Z","timestamp":1703260670000},"source":"Crossref","is-referenced-by-count":2,"title":["Health phenome of Parkinson\u2019s patients reveals prominent mood-sleep cluster"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-1758","authenticated-orcid":false,"given":"Abby","family":"Olsen","sequence":"first","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Locascio","sequence":"additional","affiliation":[{"name":"Center for Advanced Parkinson Research, Harvard Medical School, Brigham & Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idil","family":"Tuncali","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Laroussi","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Abatzis","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Kamenskaya","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Kuras","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Yi","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleks","family":"Videnovic","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hayes","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7004-8630","authenticated-orcid":false,"given":"Gary","family":"Ho","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Paulson","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-5527","authenticated-orcid":false,"given":"Vikram","family":"Khurana","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Herrington","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Hyman","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Selkoe","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Growdon","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gomperts","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Riise","sequence":"additional","affiliation":[{"name":"University of Bergen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6019-8280","authenticated-orcid":false,"given":"Michael","family":"Schwarzschild","sequence":"additional","affiliation":[{"name":"Mass. General Hospital, Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Hung","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Wills","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Scherzer","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41588-021-00847-6","article-title":"Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson\u2019s disease","volume":"53","author":"Liu G","year":"2021","unstructured":"Liu, G. et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson\u2019s disease. Nat Genet 53, 787\u2013793 (2021).","journal-title":"Nat Genet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls MA","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 18, 1091\u20131102 (2019).","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"52ra73","DOI":"10.1126\/scitranslmed.3001059","article-title":"PGC-1\u03b1, a potential therapeutic target for early intervention in Parkinson\u2019s disease","volume":"2","author":"Zheng B","year":"2010","unstructured":"Zheng, B. et al. PGC-1\u03b1, a potential therapeutic target for early intervention in Parkinson\u2019s disease. Sci Transl Med 2, 52ra73 (2010).","journal-title":"Sci Transl Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia LV","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet 386, 896\u2013912 (2015).","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention","volume":"15","author":"Ascherio A","year":"2016","unstructured":"Ascherio, A. & Schwarzschild, M. A. The epidemiology of Parkinson\u2019s disease: risk factors and prevention. Lancet Neurol 15, 1257\u20131272 (2016).","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.23687","article-title":"Meta-analysis of early nonmotor features and risk factors for Parkinson disease","volume":"72","author":"Noyce AJ","year":"2012","unstructured":"Noyce, A. J. et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 72, 893\u2013901 (2012).","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41531-019-0077-5","article-title":"The Parkinson\u2019s phenome-traits associated with Parkinson\u2019s disease in a broadly phenotyped cohort","volume":"5","author":"Heilbron K","year":"2019","unstructured":"Heilbron, K. et al. The Parkinson\u2019s phenome-traits associated with Parkinson\u2019s disease in a broadly phenotyped cohort. NPJ Parkinsons Dis 5, 4 (2019).","journal-title":"NPJ Parkinsons Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.29309","article-title":"Neuromelanin-Sensitive Magnetic Resonance Imaging Changes in the Locus Coeruleus\/Subcoeruleus Complex in Patients with Typical and Atypical Parkinsonism","volume":"38","author":"Nobileau A","year":"2023","unstructured":"Nobileau, A. et al. Neuromelanin-Sensitive Magnetic Resonance Imaging Changes in the Locus Coeruleus\/Subcoeruleus Complex in Patients with Typical and Atypical Parkinsonism. Mov Disord 38, 479\u2013484 (2023).","journal-title":"Mov Disord"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4103\/1673-5374.270297","article-title":"Locus coeruleus-norepinephrine: basic functions and insights into Parkinson\u2019s disease","volume":"15","author":"Bari BA","year":"2020","unstructured":"Bari, B. A., Chokshi, V. & Schmidt, K. Locus coeruleus-norepinephrine: basic functions and insights into Parkinson\u2019s disease. Neural Regen Res 15, 1006\u20131013 (2020).","journal-title":"Neural Regen Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e35551","DOI":"10.1097\/MD.0000000000035551","article-title":"Restless legs syndrome affects sleep in de novo Parkinson\u2019s disease patients","volume":"102","author":"Kim J-M","year":"2023","unstructured":"Kim, J.-M., Choi, S.-M., Cho, S. H. & Kim, B. C. Restless legs syndrome affects sleep in de novo Parkinson\u2019s disease patients. Medicine (Baltimore) 102, e35551 (2023).","journal-title":"Medicine (Baltimore)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16109","article-title":"Prevalence and clinical aspects of obstructive sleep apnea in Parkinson disease: A meta-analysis","author":"Maggi G","year":"2023","unstructured":"Maggi, G., Giacobbe, C., Iannotta, F., Santangelo, G. & Vitale, C. Prevalence and clinical aspects of obstructive sleep apnea in Parkinson disease: A meta-analysis. Eur J Neurol (2023) doi:10.1111\/ene.16109.","journal-title":"Eur J Neurol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/WNP.0000000000000934","article-title":"Restless Legs Syndrome and Periodic Limb Movements of Sleep: From Neurophysiology to Clinical Practice","volume":"40","author":"Kouri I","year":"2023","unstructured":"Kouri, I., Junna, M. R. & Lipford, M. C. Restless Legs Syndrome and Periodic Limb Movements of Sleep: From Neurophysiology to Clinical Practice. J Clin Neurophysiol 40, 215\u2013223 (2023).","journal-title":"J Clin Neurophysiol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1212\/WNL.0000000000001684","article-title":"Depression and subsequent risk of Parkinson disease: A nationwide cohort study","volume":"84","author":"Gustafsson H","year":"2015","unstructured":"Gustafsson, H., Nordstr\u00f6m, A. & Nordstr\u00f6m, P. Depression and subsequent risk of Parkinson disease: A nationwide cohort study. Neurology 84, 2422\u20132429 (2015).","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/npjparkd.2015.13","article-title":"The range and nature of non-motor symptoms in drug-naive Parkinson\u2019s disease patients: a state-of-the-art systematic review","volume":"1","author":"Zis P","year":"2015","unstructured":"Zis, P., Erro, R., Walton, C. C., Sauerbier, A. & Chaudhuri, K. R. The range and nature of non-motor symptoms in drug-naive Parkinson\u2019s disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis 1, 15013 (2015).","journal-title":"NPJ Parkinsons Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"101759","DOI":"10.1016\/j.smrv.2023.101759","article-title":"Sleep and wakefulness disturbances in Parkinson\u2019s disease: A meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia","volume":"68","author":"Maggi G","year":"2023","unstructured":"Maggi, G., Vitale, C., Cerciello, F. & Santangelo, G. Sleep and wakefulness disturbances in Parkinson\u2019s disease: A meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. Sleep Med Rev 68, 101759 (2023).","journal-title":"Sleep Med Rev"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5665\/sleep.3416","article-title":"Restless legs syndrome: an early clinical feature of Parkinson disease in men","volume":"37","author":"Wong JC","year":"2014","unstructured":"Wong, J. C., Li, Y., Schwarzschild, M. A., Ascherio, A. & Gao, X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep 37, 369\u2013372 (2014).","journal-title":"Sleep"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/archneur.59.3.421","article-title":"Exploring the relationship between Parkinson disease and restless legs syndrome","volume":"59","author":"Ondo WG","year":"2002","unstructured":"Ondo, W. G., Vuong, K. D. & Jankovic, J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 59, 421\u2013424 (2002).","journal-title":"Arch Neurol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1212\/WNL.0000000000200235","article-title":"Neuroprotective Trials in REM Sleep Behavior Disorder: The Way Forward Becomes Clearer","volume":"99","author":"Postuma RB","year":"2022","unstructured":"Postuma, R. B. Neuroprotective Trials in REM Sleep Behavior Disorder: The Way Forward Becomes Clearer. Neurology 99, 19\u201325 (2022).","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11910-013-0409-5","article-title":"Depression and Parkinson\u2019s disease: current knowledge","volume":"13","author":"Marsh L","year":"2013","unstructured":"Marsh, L. Depression and Parkinson\u2019s disease: current knowledge. Curr Neurol Neurosci Rep 13, 409 (2013).","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.31083\/j.fbs1401004","article-title":"Integrated pathophysiology of schizophrenia, major depression, and bipolar disorder as monoamine axon disorder","volume":"14","author":"Nakamura S","year":"2022","unstructured":"Nakamura, S. Integrated pathophysiology of schizophrenia, major depression, and bipolar disorder as monoamine axon disorder. Front Biosci (Schol Ed) 14, 4 (2022).","journal-title":"Front Biosci (Schol Ed)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00702-022-02559-5","article-title":"The pathobiological basis of depression in Parkinson disease: challenges and outlooks","volume":"129","author":"Jellinger KA","year":"2022","unstructured":"Jellinger, K. A. The pathobiological basis of depression in Parkinson disease: challenges and outlooks. J Neural Transm (Vienna) 129, 1397\u20131418 (2022).","journal-title":"J Neural Transm (Vienna)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archpsyc.64.3.327","article-title":"The role of dopamine in the pathophysiology of depression","volume":"64","author":"Dunlop BW","year":"2007","unstructured":"Dunlop, B. W. & Nemeroff, C. B. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64, 327\u2013337 (2007).","journal-title":"Arch Gen Psychiatry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1126\/science.abl6618","article-title":"Rapid eye movement sleep is initiated by basolateral amygdala dopamine signaling in mice","volume":"375","author":"Hasegawa E","year":"2022","unstructured":"Hasegawa, E. et al. Rapid eye movement sleep is initiated by basolateral amygdala dopamine signaling in mice. Science 375, 994\u20131000 (2022).","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.parkreldis.2019.03.025","article-title":"Progressive loss of raphe nuclei serotonin transporter in early Parkinson\u2019s disease: A longitudinal 123I-FP-CIT SPECT study","volume":"77","author":"Pasquini J","year":"2020","unstructured":"Pasquini, J., Ceravolo, R., Brooks, D. J., Bonuccelli, U. & Pavese, N. Progressive loss of raphe nuclei serotonin transporter in early Parkinson\u2019s disease: A longitudinal 123I-FP-CIT SPECT study. Parkinsonism Relat Disord 77, 170\u2013175 (2020).","journal-title":"Parkinsonism Relat Disord"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fphar.2020.00435","article-title":"The Noradrenergic System in Parkinson\u2019s Disease","volume":"11","author":"Paredes-Rodriguez E","year":"2020","unstructured":"Paredes-Rodriguez, E., Vegas-Suarez, S., Morera-Herreras, T., De Deurwaerdere, P. & Miguelez, C. The Noradrenergic System in Parkinson\u2019s Disease. Front Pharmacol 11, 435 (2020).","journal-title":"Front Pharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.nicl.2018.03.001","article-title":"Serotonergic dysregulation is linked to sleep problems in Parkinson\u2019s disease","volume":"18","author":"Wilson H","year":"2018","unstructured":"Wilson, H., Giordano, B., Turkheimer, F. E., Chaudhuri, K. R. & Politis, M. Serotonergic dysregulation is linked to sleep problems in Parkinson\u2019s disease. Neuroimage Clin 18, 630\u2013637 (2018).","journal-title":"Neuroimage Clin"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/da.20642","article-title":"Current perspectives of the roles of the central norepinephrine system in anxiety and depression","volume":"27","author":"Goddard AW","year":"2010","unstructured":"Goddard, A. W. et al. Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety 27, 339\u2013350 (2010).","journal-title":"Depress Anxiety"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1016\/j.cub.2021.09.041","article-title":"Noradrenergic circuit control of non-REM sleep substates","volume":"31","author":"Osorio-Forero A","year":"2021","unstructured":"Osorio-Forero, A. et al. Noradrenergic circuit control of non-REM sleep substates. Curr Biol 31, 5009\u20135023.e7 (2021).","journal-title":"Curr Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/brain\/awaa238","article-title":"Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study","volume":"143","author":"Horsager J","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41582-023-00802-5","article-title":"The noradrenergic subtype of Parkinson disease: from animal models to clinical practice","volume":"19","author":"Ray Chaudhuri K","year":"2023","unstructured":"Ray Chaudhuri, K., Leta, V., Bannister, K., Brooks, D. J. & Svenningsson, P. The noradrenergic subtype of Parkinson disease: from animal models to clinical practice. Nat Rev Neurol 19, 333\u2013345 (2023).","journal-title":"Nat Rev Neurol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/bs.irn.2017.05.024","article-title":"Depression and Anxiety in Parkinson\u2019s Disease","volume":"133","author":"Schrag A","year":"2017","unstructured":"Schrag, A. & Taddei, R. N. Depression and Anxiety in Parkinson\u2019s Disease. Int Rev Neurobiol 133, 623\u2013655 (2017).","journal-title":"Int Rev Neurobiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/oxfordjournals.aje.a120874","article-title":"C. A retrospective study of smoking in Parkinson\u2019s disease","volume":"88","author":"Nefzger MD","year":"1968","unstructured":"Nefzger, M. D., Quadfasel, F. A. & Karl, V. C. A retrospective study of smoking in Parkinson\u2019s disease. Am J Epidemiol 88, 149\u2013158 (1968).","journal-title":"Am J Epidemiol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e0151841","DOI":"10.1371\/journal.pone.0151841","article-title":"Association between Parkinson\u2019s Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis","volume":"11","author":"Breckenridge CB","year":"2016","unstructured":"Breckenridge, C. B., Berry, C., Chang, E. T., Sielken, R. L. & Mandel, J. S. Association between Parkinson\u2019s Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis. PLoS One 11, e0151841 (2016).","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neuro.2019.02.008","article-title":"Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson\u2019s disease","volume":"73","author":"Yang J","year":"2019","unstructured":"Yang, J. et al. Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson\u2019s disease. Neurotoxicology 73, 175\u2013182 (2019).","journal-title":"Neurotoxicology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bbadis.2017.02.002","article-title":"Nicotine slows down oligomerisation of \u03b1-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson\u2019s disease","volume":"1863","author":"Kardani J","year":"2017","unstructured":"Kardani, J., Sethi, R. & Roy, I. Nicotine slows down oligomerisation of \u03b1-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson\u2019s disease. Biochim Biophys Acta Mol Basis Dis 1863, 1454\u20131463 (2017).","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref36","author":"Dunn AR","year":"2017","unstructured":"Dunn, A. R. et al. Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 114, E2253\u2013E2262 (2017)."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s40478-018-0625-y","article-title":"Nicotine promotes neuron survival and partially protects from Parkinson\u2019s disease by suppressing SIRT6","volume":"6","author":"Nicholatos JW","year":"2018","unstructured":"Nicholatos, J. W. et al. Nicotine promotes neuron survival and partially protects from Parkinson\u2019s disease by suppressing SIRT6. Acta Neuropathol Commun 6, 120 (2018).","journal-title":"Acta Neuropathol Commun"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ene.13474","article-title":"High-dose transdermal nicotine in Parkinson\u2019s disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study","volume":"25","author":"Villafane G","year":"2018","unstructured":"Villafane, G. et al. High-dose transdermal nicotine in Parkinson\u2019s disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study. Eur J Neurol 25, 120\u2013127 (2018).","journal-title":"Eur J Neurol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/1531-8257(199911)14:6<1011::AID-MDS1016>3.0.CO;2-F","article-title":"Worsening of motor performance in patients with Parkinson\u2019s disease following transdermal nicotine administration","volume":"14","author":"Ebersbach G","year":"1999","unstructured":"Ebersbach, G. et al. Worsening of motor performance in patients with Parkinson\u2019s disease following transdermal nicotine administration. Mov Disord 14, 1011\u20131013 (1999).","journal-title":"Mov Disord"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1212\/WNL.57.6.1032","article-title":"Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study","volume":"57","author":"Vieregge A","year":"2001","unstructured":"Vieregge, A., Sieberer, M., Jacobs, H., Hagenah, J. M. & Vieregge, P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 57, 1032\u20131035 (2001).","journal-title":"Neurology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3233\/JPD-223291","article-title":"Association Between Parkinson\u2019s Disease and Coronary Artery Disease: A Systematic Review and Meta-Analysis","volume":"12","author":"Chua SKK","year":"2022","unstructured":"Chua, S. K. K., Saffari, S. E., Lee, S. J. Y. & Tan, E.-K. Association Between Parkinson\u2019s Disease and Coronary Artery Disease: A Systematic Review and Meta-Analysis. J Parkinsons Dis 12, 1737\u20131748 (2022).","journal-title":"J Parkinsons Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/mds.27492","article-title":"Baseline predictors for progression 4 years after Parkinson\u2019s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)","volume":"34","author":"Mollenhauer B","year":"2019","unstructured":"Mollenhauer, B. et al. Baseline predictors for progression 4 years after Parkinson\u2019s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Disord 34, 67\u201377 (2019).","journal-title":"Mov Disord"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/mds.27681","article-title":"Association of statin use with Parkinson\u2019s disease: Dose-response relationship","volume":"34","author":"Jeong S-M","year":"2019","unstructured":"Jeong, S.-M., Jang, W. & Shin, D. W. Association of statin use with Parkinson\u2019s disease: Dose-response relationship. Mov Disord 34, 1014\u20131021 (2019).","journal-title":"Mov Disord"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"e0175054","DOI":"10.1371\/journal.pone.0175054","article-title":"Statin adherence and the risk of Parkinson\u2019s disease: A population-based cohort study","volume":"12","author":"Rozani V","year":"2017","unstructured":"Rozani, V. et al. Statin adherence and the risk of Parkinson\u2019s disease: A population-based cohort study. PLoS One 12, e0175054 (2017).","journal-title":"PLoS One"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbr.2016.04.046","article-title":"Statin use and risk of Parkinson\u2019s disease: A meta-analysis","volume":"309","author":"Sheng Z","year":"2016","unstructured":"Sheng, Z., Jia, X. & Kang, M. Statin use and risk of Parkinson\u2019s disease: A meta-analysis. Behav Brain Res 309, 29\u201334 (2016).","journal-title":"Behav Brain Res"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00415-012-6606-3","article-title":"Statin use and risk of Parkinson\u2019s disease: a meta-analysis of observational studies","volume":"260","author":"Undela K","year":"2013","unstructured":"Undela, K., Gudala, K., Malla, S. & Bansal, D. Statin use and risk of Parkinson\u2019s disease: a meta-analysis of observational studies. J Neurol 260, 158\u2013165 (2013).","journal-title":"J Neurol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s10072-017-3076-5","article-title":"Head trauma and Parkinson\u2019s disease: results from an Italian case-control study","volume":"38","author":"Nicoletti A","year":"2017","unstructured":"Nicoletti, A. et al. Head trauma and Parkinson\u2019s disease: results from an Italian case-control study. Neurol Sci 38, 1835\u20131839 (2017).","journal-title":"Neurol Sci"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/oemed-2013-101444","article-title":"Head injuries and Parkinson\u2019s disease in a case-control study","volume":"70","author":"Harris MA","year":"2013","unstructured":"Harris, M. A., Shen, H., Marion, S. A., Tsui, J. K. C. & Teschke, K. Head injuries and Parkinson\u2019s disease in a case-control study. Occup Environ Med 70, 839\u2013844 (2013).","journal-title":"Occup Environ Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/mds.25458","article-title":"Head injury and risk of Parkinson disease: a systematic review and meta-analysis","volume":"28","author":"Jafari S","year":"2013","unstructured":"Jafari, S., Etminan, M., Aminzadeh, F. & Samii, A. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov Disord 28, 1222\u20131229 (2013).","journal-title":"Mov Disord"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1212\/WNL.0000000000001362","article-title":"Head injury and risk for Parkinson disease: results from a Danish case-control study","volume":"84","author":"Kenborg L","year":"2015","unstructured":"Kenborg, L. et al. Head injury and risk for Parkinson disease: results from a Danish case-control study. Neurology 84, 1098\u20131103 (2015).","journal-title":"Neurology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/mds.25143","article-title":"Head injury and Parkinson\u2019s disease: a population-based study","volume":"27","author":"Fang F","year":"2012","unstructured":"Fang, F. et al. Head injury and Parkinson\u2019s disease: a population-based study. Mov Disord 27, 1632\u20131635 (2012).","journal-title":"Mov Disord"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.parkreldis.2008.02.004","article-title":"L. A nationwide population study of severe head injury and Parkinson\u2019s disease","volume":"15","author":"Spangenberg S","year":"2009","unstructured":"Spangenberg, S., Hannerz, H., T\u00fcchsen, F. & Mikkelsen, K. L. A nationwide population study of severe head injury and Parkinson\u2019s disease. Parkinsonism Relat Disord 15, 12\u201314 (2009).","journal-title":"Parkinsonism Relat Disord"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"a2494","DOI":"10.1136\/bmj.a2494","article-title":"Risk of Parkinson\u2019s disease after hospital contact for head injury: population based case-control study","volume":"337","author":"Rugbjerg K","year":"2008","unstructured":"Rugbjerg, K., Ritz, B., Korbo, L., Martinussen, N. & Olsen, J. H. Risk of Parkinson\u2019s disease after hospital contact for head injury: population based case-control study. BMJ 337, a2494 (2008).","journal-title":"BMJ"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.parkreldis.2015.12.005","article-title":"Head injury at early ages is associated with risk of Parkinson\u2019s disease","volume":"23","author":"Taylor KM","year":"2016","unstructured":"Taylor, K. M. et al. Head injury at early ages is associated with risk of Parkinson\u2019s disease. Parkinsonism Relat Disord 23, 57\u201361 (2016).","journal-title":"Parkinsonism Relat Disord"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1289\/ehp.1002839","article-title":"Rotenone, paraquat, and Parkinson\u2019s disease","volume":"119","author":"Tanner CM","year":"2011","unstructured":"Tanner, C. M. et al. Rotenone, paraquat, and Parkinson\u2019s disease. Environ Health Perspect 119, 866\u2013872 (2011).","journal-title":"Environ Health Perspect"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3233\/JPD-191882","article-title":"Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson\u2019s Disease in the Harvard Biomarkers Study","volume":"10","author":"Bakshi R","year":"2020","unstructured":"Bakshi, R. et al. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson\u2019s Disease in the Harvard Biomarkers Study. J Parkinsons Dis 10, 505\u2013510 (2020).","journal-title":"J Parkinsons Dis"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1111\/all.12758","article-title":"Risk of developing Parkinson\u2019s disease among patients with asthma: a nationwide longitudinal study","volume":"70","author":"Cheng C-M","year":"2015","unstructured":"Cheng, C.-M. et al. Risk of developing Parkinson\u2019s disease among patients with asthma: a nationwide longitudinal study. Allergy 70, 1605\u20131612 (2015).","journal-title":"Allergy"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/qjmed\/hcu136","article-title":"The association between chronic obstructive pulmonary disease and Parkinson\u2019s disease: a nationwide population-based retrospective cohort study","volume":"108","author":"Li C-H","year":"2015","unstructured":"Li, C.-H. et al. The association between chronic obstructive pulmonary disease and Parkinson\u2019s disease: a nationwide population-based retrospective cohort study. QJM 108, 39\u201345 (2015).","journal-title":"QJM"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease","volume":"357","author":"Mittal S","year":"2017","unstructured":"Mittal, S. et al. \u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease. Science 357, 891\u2013898 (2017).","journal-title":"Science"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/mds.108","article-title":"\u03b22-adrenoceptor agonists and antagonists and risk of Parkinson\u2019s disease","volume":"33","author":"Gronich N","year":"2018","unstructured":"Gronich, N. et al. \u03b22-adrenoceptor agonists and antagonists and risk of Parkinson\u2019s disease. Mov Disord 33, 1465\u20131471 (2018).","journal-title":"Mov Disord"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/medicina57101006","article-title":"Association between \u03b22-Adrenoreceptor Medications and Risk of Parkinson\u2019s Disease: A Meta-Analysis","volume":"57","author":"Chen C-L","year":"2021","unstructured":"Chen, C.-L., Wang, S.-Y., Chen, T.-C. & Chuang, C.-S. Association between \u03b22-Adrenoreceptor Medications and Risk of Parkinson\u2019s Disease: A Meta-Analysis. Medicina (Kaunas) 57, 1006 (2021).","journal-title":"Medicina (Kaunas)"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/mds.27099","article-title":"The emerging science of precision medicine and pharmacogenomics for Parkinson\u2019s disease","volume":"32","author":"Payami H","year":"2017","unstructured":"Payami, H. The emerging science of precision medicine and pharmacogenomics for Parkinson\u2019s disease. Mov Disord 32, 1139\u20131146 (2017).","journal-title":"Mov Disord"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3683455\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3683455\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T11:16:35Z","timestamp":1706699795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3683455\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":62,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3683455\/v1","relation":{},"subject":[],"published":{"date-parts":[[2023,12,22]]},"subtype":"preprint"}}